Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av Andecaliximab hos deltakere med Fibrodysplasia Ossificans Progressiva (FOP) (ANDECAL)

3. november 2026 oppdatert av: Ashibio Inc

En fase 2/3, global, multisenter, randomisert, dobbeltblind, placebokontrollert, todelt studie med åpen etikettutvidelse (OLE) for å vurdere effekten og sikkerheten til Andecaliximab hos deltakere med Fibrodysplasia Ossificans Progressiva (FOP)

This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP.

The study is looking at several research questions, including:

  • Safety of andecaliximab in participants with FOP
  • Whether andecaliximab reduces the number of new heterotopic bone lesions (Heterotopic Ossification; HO)
  • Whether andecaliximab reduces the number or severity of flare-ups
  • Pharmacokinetics/pharmacodynamics (PK/PD): How much study drug is in your blood at different times and its impact on blood biomarker(s)
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Studieoversikt

Detaljert beskrivelse

The ASH-FOP-201 Study consists of 2 parts: Part 1 is a Lead-in Study to assess safety, PK/PD and preliminary efficacy; Part 2 is the Main Study, a Phase 2/3 randomized, double-blind, placebo-controlled trial.

Part 1 is composed of Part 1a, a Na18F positron emission tomography (PET)/computed tomography, less head (CT) Study in up to 6 participants age ≥ 15 years, and Part 1b, a flare-up Study in up to 6 participants ≥ 12 years of age. Participants enrolled in Part 1 will be randomized to one of two dose levels for 13 weeks. Participants in Part 2 will be randomized to one of two dose levels of drug vs. placebo during the 52 week trial. All participants in Part 1 or Part2 will receive study drug in the extension period of the trial.

Studietype

Intervensjonell

Registrering (Antatt)

92

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • California
      • San Francisco, California, Forente stater, 94143
        • University of California San Francisco (UCSF)
    • Minnesota
      • Rochester, Minnesota, Forente stater, 55905
        • Mayo Clinic
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • University of Pennsylvania - Perelman Center for Advanced Medicine

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

2 år og eldre (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria (Part 1a, 1b, and 2):

  1. Participant and/or guardian able and willing to give informed consent and/or assent as applicable, and willing to adhere to the visits schedule and study procedures.
  2. Clinical diagnosis of FOP including congenital malformation(s) consistent with FOP (e.g., of the great toes), and either episodic soft tissue swelling consistent with an FOP flare-up and/or progressive HO.

4. CAJIS score of ≤19. 5. Disease activity within 1 year of screening visit. Disease activity is defined as physician confirmed flare-up like symptoms or clinical progression including newly identified HO or worsening joint function.

6. Able to understand, undergo, and perform all protocol related procedures, including low-dose WBCT-LH scan without sedation. Assistance from a caregiver is allowed.

7. Agree to provide access to all relevant current and historical medical records (including radiographs or radiographic records) and growth records.

Inclusion Criteria (Part 1a only):

  1. Male or female ≥ 15 years of age.
  2. Serum creatinine ≤ upper limit of normal for age.
  3. No open growth plates on bilateral PA hand/wrist or AP knee films at baseline
  4. Able to receive IV radiotracer [both IV access and no history of a reaction to radiotracer].
  5. No use of bisphosphonates or bone active agent within the past year.
  6. At least 1 active HO lesion at baseline per Na18F PET/CT

Additional inclusion criteria apply including those listed above for all parts of the study.

Inclusion Criteria (Part 1b only):

  1. Male or female ≥12 years of age.

  2. History of multiple flare-up episodes within the past 6 months (to be reviewed and confirmed as qualifying by the PI together with the Sponsor). Qualifying flare-up episodes include any of the following:

    • At least 3 qualifying flare-ups in the past 6 months each with continuous symptoms for at least 1 week
    • Migratory flare-up swellings across the back
    • Multiple flare-up episodes the sum of which lasted at least 21 days The timing of the individual flare-ups can be overlapping; they may be ongoing at the time of enrollment or resolved.
  3. The qualifying flare-ups must involve at least 2 of the following flare-up symptoms:

    • Pain
    • Soft tissue swelling
    • Warmth
    • Redness
    • Joint stiffness
    • Decreased range of motion

Additional inclusion criteria apply including those listed above for all parts of the study.

Inclusion Criteria (Part 2 only):

  1. Initial enrollment age requirement is ≥12 years
  2. Enrollment may be extended to participants ≥6 years of age after safety in adult and participants age 12-17 years has been established.
  3. Enrollment of participants ≥2 to <6 years of age will commence after safety in adult and participants ≥6 years of age has been established.

Additional inclusion criteria apply including those listed above for all parts of the study.

Exclusion Criteria:

  1. Body weight <10kg

  2. Known non-healed fracture at time of Study Day 1.

  3. Planned surgery within the timeframe of the study duration or still recovering from recent surgery.

  4. Respiratory compromise that requires use of supplemental oxygen.

  5. Participant has

    • Known monogenic disorder other than FOP.
    • Bone or mineral disorder unrelated to FOP.
  6. Malignancy (within the past 5 years, except non-melanoma skin cancer, cervical carcinoma in situ, or ductal carcinoma in situ [DCIS]).

  7. Known active infection (including fungal, bacterial, mycobacterial, or viral infection including COVID19)

  8. Uncontrolled hypoparathyroidism or hyperparathyroidism.

  9. Per participant report or chart review (no testing required): Uncontrolled hyperthyroidism

  10. Use of the following medication:

    • Systemic corticosteroids with a prednisone equivalent of >10mg/day within 1 week of Study Day 1. If the participant requires chronic use of >10mg/day prednisone equivalent of corticosteroids, eligibility will be discussed with the Sponsor.
    • NSAIDs of higher than doses recommended by the May 2022 ICCFOP guidelines within 1 week of Study Day 1. If the participant requires chronic use of NSAIDs at doses higher than those recommended by the May 2022 ICCFOP guidelines doses, eligibility will be discussed with the Sponsor.
    • Current or chronic use of tetracycline drugs (e.g., tetracycline, demeclocycline, doxycycline, or minocycline).
  11. Chronic use of any of unproven therapies for FOP.

  12. Palovarotene

    • Within 1 month of Study Day 1 for all participants
    • Within 2 years of Study Day 1 for female participants <8 years of age Or male participants <10 years of age
  13. Treatment with another investigational product within 5 half lives of last dose at the time of Study Day 1 or 1 month, whichever is longer.

  14. History of allergy or hypersensitivity to andecaliximab or its excipients.

  15. Significant current laboratory abnormalities

  16. Breastfeeding, pregnant, or planning pregnancy.

  17. Those of childbearing potential unwilling to agree to abstain from sexual activity that could result in pregnancy or unwillingness to use acceptable birth control during the study and for 90 days after the last dose.

  18. Simultaneous participation in another clinical trial involving another investigational product.

  19. Significant medical condition or disability or biochemical or hematologic abnormalities that in the opinion of the Investigator would expose the participant to undue risk, prevent the conduct of study procedures, or confound the study results.

Note: Other protocol defined Inclusion/Exclusion Criteria apply

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part 1a: PET/CT Study

a 13-week double-blind (Investigator and Participant blinded; Sponsor unblinded) Study to assess the impact of two dose levels of andecaliximab administered subcutaneously (SC), once-a-week (QW) in participants age ≥ 15 years, with FOP on a number of outcomes including Safety, Pharmacokinetic (PK) and pharmacodynamic (PD) and the change from baseline of Na18F uptake in HO lesions by PET/CT scan, and Patient Reported Outcomes (PROs).

Dose level A or B

Dose level A or B (or age adjusted dose)

Eksperimentell: Part 1b: Flare-up Study

a 13-week double-blind (Investigator and Participant blinded; Sponsor unblinded) study to assess the impact of two dose levels of andecaliximab administered SC QW in participants ≥12 years of age with a recent history of frequent flare-up episodes on a number of outcomes including safety, PK/PD, and flare-up incidence and symptoms and PROs.

Dose level A or B

Dose level A or B (or age adjusted dose)

Placebo komparator: Part 2: Main Study

1-year (52-week) double-blind (Investigator, participant, and sponsor all blinded), placebo-controlled study of andecaliximab Dose level A or B (or age adjusted) SC QW or placebo in pediatric and adult patients with FOP. The Main Study will enroll approximately 80 participants, randomized in a 1:1:1 ratio to andecaliximab Dose level A or B (or age adjusted) SC QW or placebo.

Dose level A or B

Dose level A or B (or age adjusted dose)

Blinded

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of New HO Lesions as Assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)]
Tidsramme: Week 27 and 53

Low dose WBCT-LH (whole body CT less head) is used to create detailed images of soft tissues and bones.

Week 27 and 53

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Endring i HO-volum over tid som vurdert av WBCT-LH [Hele kroppen, datastyrt tomografi (CT), ikke inkludert hodet (mindre hode)]
Tidsramme: Uke 27 og 53
Uke 27 og 53
Antall oppblussinger rapportert av deltakeren
Tidsramme: Uke 14, 27 og 53
Uke 14, 27 og 53
Antall oppblussinger rapportert av deltakeren og bekreftet av hovedetterforskeren
Tidsramme: Uke 14, 27 og 53
Uke 14, 27 og 53
Percent change from baseline in Na18F standardized uptake value maximum (SUVmax) of up to 7 individual HO lesion(s) per participant active at baseline as assessed by Na18F PET/CT (Part 1a).
Tidsramme: Week 14

SUV max is the SUV of the most intense voxel within a region of interest.

Week 14
Change in HO volume over time as assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)] (Part 1a)
Tidsramme: Week 14

Low dose WBCT-LH (whole body CT less head) is used to create detailed images of soft tissues and bones. In Part 1a, the WBCT-LH scan will be acquired as part of the PET/CT scan at baseline and Week 14.

Week 14
Number of days during which a flare-up is experienced by the participant as reported by the participant
Tidsramme: Week 14, 27 and 53

Flare-up defined as having at least two of the following symptoms: pain, soft tissue swelling, warmth, redness, joint stiffness, or decreased range of motion.

Week 14, 27 and 53
Change in patient joint involvement as assessed by Investigator using Cumulative Analog Joint Involvement Scale (CAJIS)
Tidsramme: Week 27 and 53

CAJIS is a clinician assessment of 15 major joints; each major joint rated normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30.

Week 27 and 53
Change in patient quality of life as assessed by the EuroQol 5 dimensions questionnaire with a 5-level scale (EQ-5D-5L)
Tidsramme: Week 27 and 53

EQ-5D-5L measures: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.

Week 27 and 53
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Week 27 and 53

Number of participants with Treatment-Emergent Adverse Events (AE) (TEAEs), i.e., adverse events not present at baseline or exacerbation of a pre-existing condition during the on-treatment period will be reported.

Week 27 and 53
Number of Participants With Serious Treatment-Emergent Adverse Events (Serious TEAEs)
Tidsramme: Week 27 and 53

Number of participants with Serious Treatment-Emergent Adverse Events (AE) (TEAEs), i.e, required initial/prolonged in-patient hospitalization, death, life-threatening, persistent/significant disability/incapacity, congenital anomaly/birth defect, considered as a medically important event.

Week 27 and 53
Number of Participants With TEAEs by Severity
Tidsramme: Week 27 and 53

Severity of TEAEs will be graded as follows: Mild: Does not interfere in a significantly with functioning. Moderate: Causes some impairment of functioning but is not hazardous to health. Severe: Significant impairment or incapacitation; hazardous to one's health. Number of participants with TEAEs by severity will be reported.

Week 27 and 53

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. oktober 2024

Primær fullføring (Antatt)

4. februar 2029

Studiet fullført (Antatt)

4. februar 2029

Datoer for studieregistrering

Først innsendt

17. juni 2024

Først innsendt som oppfylte QC-kriteriene

12. juli 2024

Først lagt ut (Faktiske)

18. juli 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Redacted Protocol and SAP will be made available.

IPD-delingstidsramme

After completion of the Biologics License Applications (BLA) and all participants have completed the one year extension.

Tilgangskriterier for IPD-deling

Not decided at this time

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere